Results 31 to 40 of about 319,900 (371)

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

Journal of the American Medical Association (JAMA), 2021
Importance Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the ...
K. Stephenson, Mathieu le Gars, J. Sadoff, A. M. de Groot, Dirk Heerwegh, C. Truyers, C. Atyeo, C. Loos, A. Chandrashekar, K. McMahan, Lisa H. Tostanoski, Jingyou Yu, M. Gebre, C. Jacob-Dolan, Zhenfeng Li, Shivani Patel, Lauren Peter, Jinyan Liu, E. Borducchi, Joseph P. Nkolola, Morgana Souza, C. Tan, Rebecca Zash, B. Julg, R. Nathavitharana, R. Shapiro, Ahmed Abdul Azim, C. Alonso, K. Jaegle, J. Ansel, Diane G Kanjilal, Caitlin J. Guiney, C. Bradshaw, Anna Tyler, Tatenda Makoni, Katherine E. Yanosick, M. Seaman, D. Lauffenburger, G. Alter, F. Struyf, M. Douoguih, J. van Hoof, H. Schuitemaker, D. Barouch   +43 more
semanticscholar   +1 more source

Immunogenicity and toxicity of AAV gene therapy

Frontiers in Immunology, 2022
Gene transfer using adeno-associated viral (AAV) vectors has made tremendous progress in the last decade and has achieved cures of debilitating diseases such as hemophilia A and B.
H. Ertl
semanticscholar   +1 more source

Properties of MHC class I presented peptides that enhance immunogenicity. [PDF]

PLoS Computational Biology, 2013
T-cells have to recognize peptides presented on MHC molecules to be activated and elicit their effector functions. Several studies demonstrate that some peptides are more immunogenic than others and therefore more likely to be T-cell epitopes. We set out
Jorg J A Calis, Matt Maybeno, Jason A Greenbaum, Daniela Weiskopf, Aruna D De Silva, Alessandro Sette, Can Keşmir, Bjoern Peters   +7 more
doaj   +1 more source

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.

Journal of the American Medical Association (JAMA), 2020
Importance A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed. Objective To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China.
S. Xia, Kai Duan, Yuntao Zhang, Dongyang Zhao, Huajun Zhang, Z. Xie, Xinguo Li, Cheng Peng, Yan-Bo Zhang, Wei Zhang, Y. Yang, Wei Chen, Xiaoxiao Gao, W. You, Xuewei Wang, Zejun Wang, Zhengli Shi, Yanxia Wang, Xuqin Yang, Lianghao Zhang, Lili Huang, Qian Wang, Jia Lu, Yongli Yang, Jing Guo, Wei Zhou, X. Wan, Cong Wu, Wenhui Wang, Shihe Huang, Jianhui Du, Z. Meng, A. Pan, Zhiming Yuan, S. Shen, Wanshen Guo, Xiaoming Yang   +36 more
semanticscholar   +1 more source

Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development

Frontiers in Immunology, 2023
Immunogenicity continues to pose a challenge in the development of biotherapeutics like conventional therapeutic-proteins and monoclonal antibodies as well as emerging modalities such as gene-therapy components, gene editing, and CAR T cells.
Zuben E. Sauna, Vibha Jawa, Sathy Balu-Iyer, Narendra Chirmule   +3 more
doaj   +1 more source

Orthogonal quantification of soluble inducible T-cell costimulator (ICOS) in healthy and diseased human serum

Journal of Pharmaceutical Analysis, 2022
Inducible T-cell costimulator (ICOS), a homodimeric protein expressed on the surface of activated T-cells, is being investigated as a potential therapeutic target to treat various cancers.
Kevin McKinski, Dean McNulty, Francesca Zappacosta, Mary Birchler, Matt Szapacs, Christopher Evans   +5 more
doaj  

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

npj Vaccines, 2021
As SARS-CoV-2 vaccines are deployed worldwide, a comparative evaluation is important to underpin decision-making. We here report a systematic literature review and meta-analysis of Phase I/II/III human trials and non-human primates (NHP) studies ...
I. McDonald, Sam M. Murray, C. Reynolds, D. Altmann, R. Boyton   +4 more
semanticscholar   +1 more source

Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials

Frontiers in Bioscience-Landmark, 2021
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were first detected in Wuhan, China in December 2019 and resulted in a worldwide pandemic in 2020.
Hui Xuan Lim, Masita Arip, Abdul Aziz Al-Fattah Yahaya, Seyed Davoud Jazayeri, Sibrandes Poppema, Chit Laa Poh   +5 more
doaj   +1 more source

Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial [PDF]

Clinical and Experimental Pediatrics, 2020
Background Pneumococcal diseases among children aged 0.35 μg/mL was lower for some serotypes in the GBP411 group than in the comparator group (6B: 20.83% vs. 39.22%, P=0.047 and 19A: 58.33% vs.
Jonghoon Shin, Jamaree Teeratakulpisarn, Thanyawee Puthanakit, Tuangtip Theerawit, Ji Hwa Ryu, Jinhwan Shin, Seulgi Lee, Hayoung Lee, Kyungjun An, Hun Kim   +9 more
doaj   +1 more source

Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination

Nature, 2021
Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine1,2, European health authorities recommended that patients under the age of 55 years who received one dose of ChAdOx1-S-nCoV-19 receive a second dose of the Pfizer BNT162b2 ...
B. Pozzetto, V. Legros, Sophia Djebali, V. Barateau, N. Guibert, M. Villard, Loïc Peyrot, O. Allatif, J. Fassier, A. Massardier-Pilonchéry, K. Brengel-Pesce, Melyssa Yaugel-Novoa, S. Denolly, B. Boson, T. Bourlet, A. Bal, M. Valette, T. Andrieu, B. Lina, Kahina Christelle Bouchra Constance Virginie Vanessa Flor Saker Compagnon Mokdad d’Aubarede Pitiot Escuret M, K. Saker, Christelle Compagnon, Bouchra Mokdad, Constance d’Aubarede, V. Pitiot, V. Escuret, F. Morfin, M. Trabaud, Margaux Prieux, V. Dubois, L. Josset, Soizic Daniel, F. Cosset, S. Paul, T. Defrance, J. Marvel, T. Walzer, S. Trouillet-Assant   +37 more
semanticscholar   +1 more source